Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Income from Continuing Operations for 7 consecutive years, with 13890000.0 as the latest value for Q2 2025.

  • Quarterly Income from Continuing Operations fell 200.13% to 13890000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 24773000.0 through Jun 2025, down 14.76% year-over-year, with the annual reading at 38479000.0 for FY2025, 78.26% down from the prior year.
  • Income from Continuing Operations hit 13890000.0 in Q2 2025 for Benitec Biopharma, down from 4324000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1372000.0 in Q4 2024 to a low of 13890000.0 in Q2 2025.
  • Historically, Income from Continuing Operations has averaged 5056166.67 across 5 years, with a median of 4608500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 80.21% in 2024 and later tumbled 200.13% in 2025.
  • Year by year, Income from Continuing Operations stood at 4846000.0 in 2021, then dropped by 15.95% to 5619000.0 in 2022, then dropped by 23.38% to 6933000.0 in 2023, then surged by 80.21% to 1372000.0 in 2024, then tumbled by 912.39% to 13890000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BNTC at 13890000.0 in Q2 2025, 4324000.0 in Q1 2025, and 1372000.0 in Q4 2024.